Picture loading failed.

Anti-MS4A1 therapeutic antibody (Pre-made Obinutuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Obinutuzumab (called afutuzumab until 2009) is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-385-1mg 1mg 3090
GMP-Bios-ab-385-10mg 10mg 21890
GMP-Bios-ab-385-100mg 100mg 148000
GMP-Bios-ab-385-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-MS4A1 therapeutic antibody (Pre-made Obinutuzumab biosimilar,Whole mAb)
INN Name Obinutuzumab
TargetMS4A1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure3pp3:HL:IK/3pp4:HL
99% SI Structure6y9a:HL
95-98% SI StructureNone
Year Proposed2008
Year Recommended2011
CompaniesGLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds
Conditions ApprovedChronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma
Conditions ActiveDiffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia
Conditions DiscontinuedPrimary biliary cirrhosis
Development TechGlycoMAb Technology